Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Competitors to Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Amgen Inc. 

Amgen is a leader in biotechnology and focuses on the development of innovative therapies for serious illnesses, including cancer, which aligns with Quantum Biopharma’s mission. Both companies emphasize research and development and strive to bring advanced biotech products to market quickly. Amgen's well-established infrastructure, extensive pipeline, and financial resources provide it with a competitive advantage over Quantum Biopharma as it can outpace smaller firms in product development and market penetration.

Biogen Inc. 

Biogen specializes in therapies for neurodegenerative diseases and is involved in premium gene therapies, which overlaps with some of Quantum Biopharma’s areas of focus. Both companies push for breakthroughs in treating complex diseases, but Biogen's extensive portfolio and established track record in securing FDA approvals create a challenge for Quantum Biopharma, which is still building its credibility. Biogen currently holds a stronger position in the market due to its historical success in research outcomes.

Moderna, Inc. 

Moderna gained prominence through its mRNA technology used in vaccines and is expanding its applications into other therapeutic areas. Its success during the COVID-19 pandemic has positioned it as a formidable player in the biopharmaceutical industry. While Quantum Biopharma focuses on more niche therapeutic areas, Moderna’s vast resources and technological advancements give it a competitive edge, making it a leader in innovation and market presence.

Novartis AG 

Novartis is a global healthcare company with a vast range of products, including innovative medicines in the oncology space. Their established reputation, significant financial resources, and a robust marketing strategy enable them to dominate the market. Quantum Biopharma’s emerging status means it is competing against a well-resourced and diversified competitor. Novartis's economies of scale and extensive clinical trial experience give it a leading advantage over Quantum Biopharma.

Sangamo Therapeutics, Inc. 

Sangamo is known for its genomic therapies, focusing on gene editing and genetic medicine, which may intersect with some of Quantum Biopharma's initiatives. Both companies prioritize advanced biotechnologies, but Sangamo’s established partnerships and collaborations with larger pharmaceutical firms enhance its standing. While both are competitors in cutting-edge biotech areas, Sangamo appears to have an advantage due to its broader network and advanced research capabilities.